Kineta Inc.
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (m… Read more
Kineta Inc. (KA) - Total Liabilities
Latest total liabilities as of June 2024: $9.38 Million USD
Based on the latest financial reports, Kineta Inc. (KA) has total liabilities worth $9.38 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kineta Inc. - Total Liabilities Trend (2019–2023)
This chart illustrates how Kineta Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kineta Inc. Competitors by Total Liabilities
The table below lists competitors of Kineta Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hultström Group B
ST:HULT-B
|
Sweden | Skr58.75 Million |
|
Sahathai Terminal Public Company Limited
BK:PORT
|
Thailand | ฿1.81 Billion |
|
Megapolitan Developments Tbk
JK:EMDE
|
Indonesia | Rp1.23 Trillion |
|
Group 6 Metals Ltd
AU:G6M
|
Australia | AU$115.42 Million |
|
Venari Minerals NL
AU:VMS
|
Australia | AU$1.08 Million |
|
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ:GDTC
|
USA | $892.51K |
Liability Composition Analysis (2019–2023)
This chart breaks down Kineta Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kineta Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kineta Inc. (2019–2023)
The table below shows the annual total liabilities of Kineta Inc. from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $7.22 Million | -43.86% |
| 2022-12-31 | $12.87 Million | -49.15% |
| 2021-12-31 | $25.30 Million | -29.42% |
| 2020-12-31 | $35.85 Million | +60.42% |
| 2019-12-31 | $22.35 Million | -- |